key: cord-0966308-hc4z7hyp authors: Luo, Xiao‐Hua; Zhu, Yan; Mao, Jian; Du, Rui‐Chan title: T‐cell immunobiology and cytokine storm of COVID‐19 date: 2020-10-28 journal: Scand J Immunol DOI: 10.1111/sji.12989 sha: dbed8e9e122c1c6b274d4dc4f760c5aa6840a319 doc_id: 966308 cord_uid: hc4z7hyp 2019 coronavirus disease (COVID‐19) presents as a newly recognized pneumonia and could rapidly progress into acute respiratory distress syndrome which has brought about a global pandemic. Until now, no curative therapy has been strongly recommended for COVID‐19 except for personalized supportive care. T cells and virus‐specific T cells are essential to protect against virus infection, including COVID‐19. Delayed immune reconstitution (IR) and cytokine storm (CS) remain serious obstacles for the cure of COVID‐19. Most COVID‐19 patients, especially among elderly patients, had marked lymphopenia and increased neutrophils, but T cell counts in severe COVID‐19 patients surviving the disease gradually restored later. Elevated pro‐inflammatory cytokines, particularly IL‐6, IL‐10, IL‐2, and IL‐17, and exhausted T cells are found in peripheral blood and the lungs. It suggests that Thymosin α1 and adoptive COVID‐19‐specific T cells could improve IR while convalescent plasma, IL‐6 blockade, mesenchymal stem cells, and corticosteroids could suppress CS. More clinical studies in this field worldwide are urgently warranted to pave the way for therapy of COVID‐19 in the future. Ki67, CD38, and human leukocyte antigen-DR (HLA-DR) (23, 32, 33). Peripheral CD4+ T cells in 2019-nCoV patients expressed higher levels of CD69, CD38, OX40, and CD44, while activated CD8+ T cells expressing higher levels of CD69, CD38, and CD44 (15). The percentage of naïve helper T cells (CD3+CD4+CD45RA+) increased while memory helper T cells (CD3+CD4+CD45RO+), CD28 positive cytotoxic suppressor T cells (CD3+CD8+CD28+), and regulatory T cells (CD3+CD4+CD25+CD127low+) decreased in severe cases (10), implying that the immune system in the severe COVID-19 patients was impaired more greatly. However, several reports revealed exhaustive status of T cells. A much higher percentage of Tim3+PD-1+ expressed on both CD4+ and CD8+ T cells from COVID-19 patients with severe diseases, indicating the exhaustive T cells in response to this virus infection (13, 15, (33) (34) (35) . Moreover, increased expression of PD-1 and Tim-3 on T cells could predict progression from prodromal to overtly symptomatic stages of COVID-19 (13) . Compared with the healthy control and mild group, the frequency of multi-functional CD4+ T cells (positive for at least two of cytokines IFN-γ, TNF-α, and IL-2) decreased significantly in the severe cases, whereas the proportion of non-functional subsets (IFN-γ−TNF-α−IL-2−) increased significantly (35). The frequency of the non-exhausted Pathological findings of one COVID-19 case with ARDS (36) confirmed that inflammatory lymphocytes infiltrate both lungs, which were high cytotoxic CD8 T cells and hyperactivated Th17. Furthermore, single-cell RNA sequencing uncovered lung bronchoalveolar immune cells in patients with COVID-19 (37). CD8+ T cells in bronchoalveolar lavage fluid (BALFs) from patients with severe/critical infection were less expanded, more proliferative and more phenotypically heterogeneous, whereas a larger proportion of CD8+ T cell effectors with tissue-resident and highly expanded features were present in BALFs from patients with moderate infection Accepted Article (37) . These aberrant T cell responses may enter and reside in the lung in high numbers and damage this organ lethally in severely ill patients with COVID-19. Consistent with SARS or MERS, it is striking that children always develop mild clinical disease, the elderly cases experience much worse outcomes following infection with COVID-19 (10), suggesting that mature extravagant immune responses to the novel coronavirus infection play a crucial role in triggering ARDS and organ failures. The T cell compartment undergoes senescence in the older population, which results in higher risk and severity of infections and inhibits immunogenicity and vaccine efficacy in this population. Moreover, males may be more susceptible to COVID-19 than females (38-40). Females experience a lower risk of infections and chronic inflammatory disease but are generally more vulnerable to autoimmunity (41). As the ACE2 gene localizes on the X-chromosome, ACE2 levels in the blood are higher in males than in females as well as in patients with diabetes or cardiovascular diseases (42). Therefore, male patients may be more likely to die from COVID-19 because of the high expression of ACE2, though further research on the mechanism is needed. Immunological aging may, therefore, be accounted for as injury from immune responses to novel virus infection in elderly life. Thus, constant immunosurveillance against COVID-19 seems to be more demanding for elderly males. Cytokine storm and Immunomodulatory therapy (Table 1) Cytokine storms (CS) are underlying a range of infectious and noninfectious diseases. The first use of "cytokine storm" appears to be on graft-versus-host disease published in 1993 (43) and later in virus infectious diseases including cytomegalovirus (44), EBV-associated hemophagocytic lymphohistiocytosis (45), and SARS-CoV (46). CS is thought to be an overwhelming immune reaction mediated by immune toxicity. The clinical symptoms and signs of CS affect multiple organ systems, among which acute lung injury is a typical product of damages in the lung alveoli and can progress into respiratory failure (47). SARS is an instance of cytokine storms that give rise to a robust pro-inflammatory reaction in the lungs characterized by pulmonary fibrosis, inflammation and hypercytokinemia (48). Similarly, cytokine storm is a critical profile of patients with COVID-19 defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6 (49-51). Higher plasma concentrations of IL-2, IL2R, IL-6, IL-7, IL-10, G-CSF, IP10, MCP1, MCP-3, IL-1ra, MIP1A, IFN-γ, and TNF-α were observed in ICU patients than non-ICU patients with COVID-19 (10, 17 , 52, 53), indicating that cytokine storm was related to disease severity and fatal outcome (54). A triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progression of COVID-19 (55). Lung macrophages in severe patients with COVID-19 may contribute to local inflammation by recruiting inflammatory monocytic cells and neutrophils (37). Levels of cytokine in severe patients with COVID-19 surviving the disease gradually restored to levels comparable to the mild cases (13, 17) . It is noted that C-reactive protein, ferritin, and neutrophil counts were considerably higher in severe patients than moderate patients, while eosinopenia appeared in the majority of COVID-19 patients (10, 15, 39, 56). Furthermore, the dynamic changes of T cell counts are reversely correlated with the dynamic changes of most cytokine levels in the peripheral blood in severe COVID-19 patients (17, 57) . Because the severity of COVID-19 is associated with a cytokine storm, it would be reasonable to control this storm to mitigate the self-imposed damages launched by the host anti-infection responses. The treatment of CS adheres to a grading and risk-adapted strategy (58, 59). Due to the role of IL-6 in disease pathology, the selective blockade of IL-6 signaling by the IL-6 receptor antagonist or anti-IL-6 antibody has been the backbone of CS remedy, resulting in rapid relief of CS symptoms within a few hours. Interestingly, it appears that IL-6 blockade does not suppress CAR-T cell function in humans and mice and does not impact prognosis (60-63), which may be helpful for not hurting potential anti-virus immunity in patients with COVID-19. Several reports worldwide emphasized elevated plasma concentrations of IL-6 and provided a rationale for the introduction of anti-IL-6 therapies in randomized clinical trials (64) (65) (66) (67) (68) (69) (70) . Moreover, IL-1 pathways may be another novel targets for inflammatory storm (71, 72) . It has not been definitively identified the reason that intravenous immunoglobulin (IVIG) restrains harmful inflammation. IVIG conducts several immunomodulatory roles through blocking Fc receptors, which are relevant to the tolerance of the self and the inflammation severity (73) . This tactics have been used to abate viral-triggered CS and was verified to have improved the outcome of the infection, including SARS and the 2009 H1N1 pandemic influenza (74, 75) . Administration of hyperimmune IV immunoglobulin within five days of symptom onset was associated with a decreased viral load and lower mortality in patients with severe A This article is protected by copyright. All rights reserved (H1N1) infection (74) . These reports implied that passive IVIG is a potential program for treating severe COVID-19. Corticosteroids are pretty efficient in the therapy of CS and inhibit the inflammatory response, but they also impair T cell function and may hamper the persistence and activity of anti-virus T cells. The evidence in support of the administrating corticosteroids in COVID-19 is inconclusive (76) (77) (78) , but experiences from China recommend corticosteroids treatment to be an adjuvant therapy for critically ill patients with COVID-19 at a low-to-moderate dose and short term (methylprednisolone 0.5-1/mg/kg/day, 3-5 days or shorter than 10 days) (79-82). Furthermore, pathological pulmonary edema and hyaline membrane formation indicate corticosteroids should be used timely and appropriately for severe patients with COVID-19 to prevent the occurrence of ARDS (36). The RECOVERY Collaborative Group reported that the use of dexamethasone (oral or intravenous dexamethasone at a dose of 6 mg once daily for up to 10 days, or until hospital discharge if sooner) resulted in lower 28-day mortality among patients receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support (83). Bruno M. Tomazini et al. supported that dexamethasone (dexamethasone 20 mg intravenously once daily for 5 days, followed by 10 mg intravenously once daily for additional 5 days or until ICU discharge) plus standard care resulted in longer days alive and free of mechanical ventilation over 28 days for COVID-19 patients with moderate to severe ARDS (84). It suggests that corticosteroids should be applied to patients with severe cases of COVID-19, especially for those requiring respiratory support. In refractory cases, ibrutinib, JAK inhibitors, or TNF-α blocker, T cell depleting alemtuzumab (anti-CD52 monoclonal antibody) and ATG, and N-acetylcysteine (NAC) or vitamin C or convalescent plasma or This article is protected by copyright. All rights reserved The hallmark of COVID-19 is the continued T-cell depletion, resulting in gradual immunodeficiency, secondary infection, and even death. Hypoplastic bone marrow and decreased numbers of lymphocyte, cell degeneration, and necrosis in the spleen were found pathologically in three COVID-19 cases (97, 98). Hyperactivation of T cells or high levels of expression of pro-apoptotic molecules, such as FAS (also known as CD95)8, or TRAIL, could also contribute to T cell depletion (33). SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion (99), although whether the infection induces apoptosis in T cells still need further research. T cell counts in surviving patients with severe COVID-19 gradually recovered to levels comparable to the mild cases (13, 16, 17) . Fang Gong et al. comprehensively analyzed circulating CD4+ T cells of 13 COVID-19 convalescent patients (100). They found that more severe individuals showed higher frequency of TEM and TFH-EM cells but a lower frequency of TCM, TFH-CM and TNaive cells, relative to mild and moderate patients. Immune reconstitution (IR), marked by an increase in T cell number, is the most crucial process that takes place in COVID-19 patients after treatment. Enhancing immune reconstitution, in particular COVID-19 specific T cells, therefore, is an area of urgent research. T-cell reconstitution usually depends on homeostatic peripheral expansion and thymopoiesis. Cytokine-based approaches to improve IR through peripheral expansion are mostly investigated in the field of hematopoietic stem cell transplantation (HSCT), including IL-2, IL-7, and IL-21, and so on. These cytokines could function in T-cell differentiation into effector cells and T-, B-, and NK-cell proliferation. However, early T-cell immunity through peripheral expansion is almost unavailable on account of a substantially limited T-cell receptor (TCR) diversity for this novel coronavirus, as thymopoiesis could mainly supply new TCR clones in naive T cells. Thymosin α 1 (Tα1) has been explored to enhance T-cell IR in the HSCT setting, as the thymus naturally promotes T-cell development through secreting the hormone. Subcutaneous administrations of Tα1 after allo-HSCT led to faster CD4+ T-cell recovery and pathogen-specific T cells to emerge at 1 month after transplantation, which was earlier and in higher numbers as compared to controls (101). Tα1 (Thymalfasin/Zadaxin) is an orphan drug approved by the FDA for the therapy of chronic hepatitis B without adverse effects (102). Adoptive transfer of antigen-specific T Cells seems promising to improve immune This article is protected by copyright. All rights reserved reconstitution, which has been extensively used to treat patients with refractory CMV or EBV infection (103, 104). We have developed effective methods to expand Tumor-infiltrating lymphocytes and virus-specific T cells (105, 106). Infusion of COVID-19 specific T cells could be a life-saving strategy for severe COVID-19 infected patients, considering COVID-19 specific T cells have been identified (22-26, 32). As Tim3 and PD-1 highly expressed on both CD4+ and CD8+ T cells from severe COVID-19 patients (13, 15, (33) (34) (35) , whether the reversing T cell exhaustion with immune checkpoint inhibitors (ICI) is beneficial remains unanswered at the moment. It assumes that ICI could theoretically restore exhaustive T cells in the early stage of virus infections including COVID-19 infection (107-109). Preliminary data from cancer patients with COVID-19 infection suggest PD-1 blockade exposure seemed to be not associated with increased risk of severity of COVID-19 (110). However, further studies are warranted to carefully address ICI-related side effects as hyperactivated lymphocytes and cytokine storm are might be augmented and worsen COVID-19 outcomes. Cure of COVID is often hampered by T cell deficiency and cytokine storm. Levels of T-cell subsets and cytokine storm could predict the transition from mild to severe. It indicates that during COVID-19 infection, some aspects of the immune response require strengthening at moments and require inhibiting at other moments. The immune system early in the infection, when the virus is replicating quickly and climbing its peak, could be substantially distinct from when the pathogen achieves a balance or is clearing up due to anti-virus drugs or host immune response. Variations in individuals' reactions to infection and medications are likely to be complicated and influenced by host and pathogen genetic makeup as well as by individual immune memory. Fortunately, we now have a clearer picture of this changing immune response of COVID-19, as well as its connection with age and gender. Taking into account the acme course (9.5-12 days from onset) (9, 111, 112), kinetic changes of lymphocytes and cytokines of this disease, several rational therapies identified so far to direct at the specific stage of the immune cascade and implement those at the right moment should be considered ( Figure 1 ). It suggests that Thymosin α1 and adoptive COVID-19-specific T cells could improve IR while convalescent plasma or IVIG, IL-6 blockade, MSCs, and corticosteroids could suppress CS. Timing the Accepted Article therapeutic window of checkpoint inhibitors warrants meticulous assessment, regarding the exhausted T cells at an early stage of the disease. More in-depth clinical studies in this field worldwide are urgently warranted, both in terms of reconstitution of T-cell immunobiology and abating cytokine storm, which would pave the way for therapy of COVID-19 in the future. Oxford Immunology Network Covid-19 Response TcC, Investigators IC. 2020. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology 27. Zhu This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved A novel coronavirus from patients with pneumonia in China First case of 2019 novel coronavirus in the United States Bat origin of a new human coronavirus: there and back again Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins SARS-CoV-2 infection protects against rechallenge in rhesus macaques Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets Human immunopathogenesis of severe acute respiratory syndrome (SARS) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases Accepted Article This article is protected by copyright Clinical and immunological features of severe and moderate coronavirus disease 2019 Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) The laboratory tests and host immunity of COVID-19 patients with different severity of illness Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients Functional exhaustion of antiviral lymphocytes in COVID-19 patients Chimeric antigen receptor T cells in refractory B-cell lymphomas Tocilizumab treatment in COVID-19: a single center experience The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19 Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab for the treatment of severe coronavirus disease 2019 Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report A dynamic immune response shapes COVID-19 progression Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing Accepted Article This article is protected by copyright. All rights reserved 2003. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. The Lancet Respiratory Medicine Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan, China. Frontiers in Pharmacology 11 79. 2020. National Health Commission of the People's Republic of China. The 7th trial version of Diagnosis and Treatment Scheme for Pneumonitis with 2019-nCoV Infection Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua jie he he hu xi za zhi= Zhonghua jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases On the use of corticosteroids for 2019-nCoV pneumonia Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia The authors declare no conflict of interest. No external funding was received. This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved